A rare carcinoma of the esophagus which contains squamous cells, mucus secreting cells, and cells of an intermediate type. (WHO)
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
The documentation for mucoepidermoid esophageal carcinoma is limited primarily due to its rarity. Conditions like this affect a small number of individuals, making systematic clinical studies challenging. As a result, comprehensive clinical features and genetic associations have not been thoroughly documented, contributing to the uncertainty surrounding this condition.
To navigate your care effectively, it is advisable to seek a specialist in oncology, particularly one with expertise in rare esophageal cancers. You can also explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for more information. While there are currently no patient organizations specifically identified for this condition, staying informed about clinical developments and potential registries is vital for ongoing support and research participation.
Currently, there are several orphan drug designations for mucoepidermoid esophageal carcinoma. Pembrolizumab is an FDA-approved treatment, while drugs such as 4-Methylumbelliferone and Doxorubicin HCl with pluronic L-61 and pluronic F-127 are designated for development. Unfortunately, there are no active clinical trials available at this time. For ongoing research opportunities, you can search ClinicalTrials.gov for updates on this condition.
Actionable guidance for navigating care for mucoepidermoid esophageal carcinoma
To navigate your care effectively, it is advisable to seek a specialist in oncology, particularly one with expertise in rare esophageal cancers. You can also explore resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for more information. While there are currently no patient organizations specifically identified for this condition, staying informed about clinical developments and potential registries is vital for ongoing support and research participation.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.